论文部分内容阅读
作者们将粗制人自细胞干扰素(HLI)在头顼部癌患者的局部应用结果为:30例中有10例痊愈,10例皮肤损害及上皮损害痊愈,5例肿瘤范围明显缩小而且边界清楚,2例表现为肿瘤退化,3例无效。作者们认为,干扰素在肿瘤局部的应用可以防止手术中肿瘤扩散,又可抑制转移,因此减少复发。由于最近十年已完成了人白细胞干扰素的实验室和临床研究,因此粗制干扰素于1977年引入临床来治疗头颈部癌。目前获得的证据表明:干扰素除了具有抗病毒活性之外,还具有抗肿瘤作用。干扰素抗肿瘤活性有两种表现:(1)在肿
The authors applied localized results from crude human interferon-interferon (HLI) in patients with head and neck cancer: 10 of 30 patients recovered, 10 had skin lesions and epithelial lesions healed, and 5 patients had significantly narrower tumor boundaries and borders. Clearly, 2 cases showed tumor regression and 3 cases were ineffective. The authors believe that the use of interferon in the local tumor can prevent the spread of tumors during surgery and can also inhibit metastasis, thus reducing recurrence. Since laboratory and clinical studies of human leukocyte interferon have been completed in the last decade, crude interferon was introduced in 1977 to treat head and neck cancer. Evidence currently available indicates that interferon has anti-tumor effects in addition to antiviral activity. Interferon antitumor activity has two manifestations: (1) in the swollen